Assembly Biosciences, Inc. Common Stock ASMB
i
Market dataready · fetched 2026-11-12T14:55:25.556Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T14:55:04.138151976Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-12T14:55:24.355768+00:00
Assembly Biosciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 20.32 | 85.4% | 13.9% | |||
| 40Δ | 20.98 | 82.9% | 12.4% | |||
| 45Δ | 21.63 | 80.5% | 10.9% | |||
| 50Δ | 22.29 | 78.0% | 9.3% | |||
| 55Δ | 22.05 | 112.2% | 15.5% | 22.95 | 75.5% | 7.8% |
| 60Δ | 20.78 | 116.5% | 13.7% | 23.61 | 73.0% | 6.3% |
| 65Δ | 19.51 | 120.8% | 11.9% | 24.27 | 70.5% | 4.8% |
| 70Δ | 18.24 | 125.1% | 10.1% | 24.92 | 68.0% | 3.3% |
| 75Δ | 16.97 | 129.3% | 8.4% | |||
| 80Δ | 15.71 | 133.6% | 6.6% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.32
- IV
- 85.4%
- B/E move
- 13.9%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.98
- IV
- 82.9%
- B/E move
- 12.4%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.63
- IV
- 80.5%
- B/E move
- 10.9%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.29
- IV
- 78.0%
- B/E move
- 9.3%
55Δ
- Pseudo strike
- 22.05
- IV
- 112.2%
- B/E move
- 15.5%
- Pseudo strike
- 22.95
- IV
- 75.5%
- B/E move
- 7.8%
60Δ
- Pseudo strike
- 20.78
- IV
- 116.5%
- B/E move
- 13.7%
- Pseudo strike
- 23.61
- IV
- 73.0%
- B/E move
- 6.3%
65Δ
- Pseudo strike
- 19.51
- IV
- 120.8%
- B/E move
- 11.9%
- Pseudo strike
- 24.27
- IV
- 70.5%
- B/E move
- 4.8%
70Δ
- Pseudo strike
- 18.24
- IV
- 125.1%
- B/E move
- 10.1%
- Pseudo strike
- 24.92
- IV
- 68.0%
- B/E move
- 3.3%
75Δ
- Pseudo strike
- 16.97
- IV
- 129.3%
- B/E move
- 8.4%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 15.71
- IV
- 133.6%
- B/E move
- 6.6%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 81.10% | |
| 82.92% | |
| 85.93% | |
| 89.33% | |
| 86.43% | |
| 86.83% | |
| 89.79% | |
| 90.73% | |
| 89.98% | |
| 86.91% |
Biotechnology
ASND
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
More →ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of…
More →ATOS
Description unavailable
More →AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is…
More →AURA
Description unavailable
More →AUTL
Description unavailable
More →